Literature DB >> 26556

Pharmacokinetics and steady-state myocardial uptake of disopyramide in the dog.

A Karim, C Kook, R L Novotney, J Zagarella, J Campion.   

Abstract

The pharmacokinetics and steady-state myocardial uptake of the antiarrhythmic drug disopyramide (DP) were determined in dogs after oral or intravenous administration of [14C]disopyramide phosphate. DP was absorbed rapidly and its absolute oral bioavailability was about 70%. Significant dose-dependent kinetics were not apparent after 7.5- to 30-mg/kg po doses. Plasma half-lives of DP were about 2.9 and 1.2 hr after the po and iv doses, respectively. DP and its N-dealkylated metabolites were largely excreted in the urine and their composition was qualitatively similar after the po and iv doses. Marked differences in the protein binding of DP in human and dog plasma were found. In the papillary muscle, ventricular septum, and ventricles of one dog, the steady-state concentrations of DP and its less active mono-N-dealkylated metabolite were about twice those in plasma, whereas in the atria and tricuspid and mitral valves they were similar to those in plasma.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 26556

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  7 in total

1.  Mechanism of compound- and species-specific food effects of structurally related antiarrhythmic drugs, disopyramide and bidisomide.

Authors:  C S Cook; L Zhang; J Osis; G L Schoenhard; A Karim
Journal:  Pharm Res       Date:  1998-03       Impact factor: 4.200

2.  Effect of age and plasma concentrations of albumin and alpha 1-acid glycoprotein on protein binding of disopyramide.

Authors:  D W Holt; A M Hayler; G F Healey
Journal:  Br J Clin Pharmacol       Date:  1983-09       Impact factor: 4.335

3.  Prediction of the volumes of distribution of basic drugs in humans based on data from animals.

Authors:  Y Sawada; M Hanano; Y Sugiyama; H Harashima; T Iga
Journal:  J Pharmacokinet Biopharm       Date:  1984-12

Review 4.  Clinical pharmacokinetics of disopyramide.

Authors:  A Karim; C Nissen; D L Azarnoff
Journal:  J Pharmacokinet Biopharm       Date:  1982-10

5.  Plasma binding of disopyramide.

Authors:  B M David; B W Madsen; K F Ilett
Journal:  Br J Clin Pharmacol       Date:  1980-06       Impact factor: 4.335

6.  The effect of saturable binding to plasma proteins on the pharmacokinetic properties of disopyramide.

Authors:  K M Giacomini; S E Swezey; K Turner-Tamiyasu; T F Blaschke
Journal:  J Pharmacokinet Biopharm       Date:  1982-02

7.  Canine digitalis arrhythmia as a model for detecting Na-channel blocking antiarrhythmic drugs: a comparative study using other canine arrhythmia models and the new antiarrhythmic drugs, propafenone, tocainide, and SUN 1165.

Authors:  K Hashimoto; M Ishii; S Komori; H Mitsuhashi
Journal:  Heart Vessels       Date:  1985-02       Impact factor: 2.037

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.